PLX-4032, a small-molecule B-Raf inhibitor for the potential treatment of malignant melanoma

Current Opinion in Investigational Drugs

Volumn 11, Issue 6, 2010, Pages 699-706

  Smalley, Keiran S M ^a  

^a H LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

7 ETHYL 10 HYDROXYCAMPTOTHECIN; ANTINEOPLASTIC AGENT; B RAF KINASE; BEVACIZUMAB; CAPECITABINE; DACARBAZINE; FLUORODEOXYGLUCOSE; FLUOROURACIL; MITOGEN ACTIVATED PROTEIN KINASE; OXALIPLATIN; PLX 4032; PLX 4720; RO 5185426; TANESPIMYCIN; TEMOZOLOMIDE; UNCLASSIFIED DRUG;

ALKALINE PHOSPHATASE BLOOD LEVEL; ANTINEOPLASTIC ACTIVITY; AREA UNDER THE CURVE; ARTHRALGIA; CANCER CELL CULTURE; CANCER COMBINATION CHEMOTHERAPY; CANCER INHIBITION; CANCER PATIENT; CANCER REGRESSION; CELL PROLIFERATION; CLINICAL TRIAL; COLORECTAL CANCER; COLORECTAL CARCINOMA; DRUG BIOAVAILABILITY; DRUG DEPENDENCE; DRUG EFFICACY; DRUG POTENCY; DRUG SELECTIVITY; DRUG TOLERABILITY; FATIGUE; GENE MUTATION; HUMAN; IN VITRO STUDY; IN VIVO STUDY; MELANOMA; MONOTHERAPY; NONHUMAN; OVERALL SURVIVAL; PANCYTOPENIA; PHOTOSENSITIVITY; POSITRON EMISSION TOMOGRAPHY; PROGRESSION FREE SURVIVAL; RASH; REVIEW; SIDE EFFECT; SOLID TUMOR; TREATMENT RESPONSE; WILD TYPE;

ANIMALS; HUMANS; INDOLES; MELANOMA; MOLECULAR TARGETED THERAPY; PROTEIN KINASE INHIBITORS; PROTO-ONCOGENE PROTEINS B-RAF; SULFONAMIDES;

EID: 77952936250     PISSN: 14724472     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (70)

1. Mechanism of activation of the RAF-ERK signaling pathway by oncogenic mutations of B-RAF. Wan PTC, Garnett MJ, Roe SM, Lee S, Niculescu-Duvaz D, Good VM, Jones CM, Marshall CJ, Springer CJ, Barford D, Marais R CELL 2004 116 6 855-867
2. B-Raf inhibitor fact sheet. Plexxikon Inc COMPANY BROCHURE 2005 September 30
3. Development of a novel inhibitor of oncogenic B-Raf. Tsai J, Zhang J, Bremer R, Artis R, Hirth P, Bollag G PROC AM ASSOC CANCER RES 2006 47 Abs 2412
4. BAY 43-9006 exhibits broad spectrum oral antitumor activity and targets the RAF/MEK/ERK pathway and receptor tyrosine kinases involved in tumor progression and angiogenesis. Wilhelm SM, Carter C, Tang L, Wilkie D, McNabola A, Rong H, Chen C, Zhang X, Vincent P, McHugh M, Cao Y et al CANCER RES 2004 64 19 7099-7109
5. Discovery and pre-clinical development of a novel inhibitor of oncogenic B-Raf. Ibrahim P N, Zhang J, Cho H, Mamo S, Bremer R, Gillette S, Kumar A, Fong D, Wang W, Zhu Y L, Marimuthu A et al ACS 2006 232nd San Francisco MEDI 46
6. Plexxikon and Roche enter partnership to develop targeted cancer therapeutic medicine PLX4032. Plexxikon Inc PRESS RELEASE 2006 October 05
7. Antitumor activity of PLX4032, a novel B-Raf V600E inhibitor. Lee J T Kong J, Smalley K, Tsai J, Cho H, Bollag G, Herlyn M EJC SUPPL 2006 4 12 Abs 569
8. NCT00405587: Safety study of PLX4032 in patients with solid tumors. Plexxikon Inc CLINICALTRIALS.GOV 2006
9. Demonstration of a genetic therapeutic index for tumors expressing oncogenic BRAF by the kinase inhibitor SB-590885. King AJ, Patrick DR, Batorsky RS, Ho ML, Do HT, Zhang SY, Kumar R, Rusnak DW, Takle AK, Wilson DM, Hugger E et al CANCER RES 2006 66 23 11100-11105
10. Tumor necrosis factor-á blocks apoptosis in melanoma cells when BRAF signaling is inhibited. Gray-Schopfer VC, Karasarides M, Hayward R, Marais R CANCER RES 2007 67 1 122-129
11. Protein Kinases - Informa Life Sciences' sixth annual congress, Lisbon, Portugal. IDdb author IDDB MEETING REPORT 2007 May 21-24
12. Plx4032, a selective B-RafV600E inhibitor has potent anti-tumor activity in B-RafV600E-bearing colorectal xenografts and shows additive effect with other chemoagents. Su F, Yang H, Higgin B, Chen J, Kolinsky K, Packman K, Heimbrook DC AACR-NCI-EORTC INT CONGRESS 2007 19 October 23 Abs 252
13. Discovery of a selective inhibitor of oncogenic B-Raf kinase with potent antimelanoma activity. Tsai J, Lee JT, Wang W, Zhang J, Cho H, Mamo S, Bremer R, Gillette S, Kong J, Haass NK, Sproesser K et al PROC NATL ACAD SCI USA 2008 105 8 3041-3046
14. The RAF inhibitor PLX4032 effectively suppresses MAPK signaling in cells harboring mutant BRAF, but not in cells with upstream activation of the pathway. Poulikakos PI, Joseph EW, Tsai J, Bollag G, Rosen N AM ASSOC CANCER RES ANN MEET 2008 99 April 16 Abs 5800
15. PLX4032, a selective inhibitor of RAF kinase activity, inhibits BRAFV600E tumor proliferation and MAPK signaling in vitro and in vivo. Joseph EW, Poulikakos PI, Pratilas CA, Halilovic E, Lobo J, Bollag G, Tsai J, Solit D, Rosen N AM ASSOC CANCER RES ANN MEET 2008 99 April 15 Abs 3437
16. BRAF silencing by short hairpin RNA or chemical blockade by PLX4032 leads to different responses in melanoma and thyroid carcinoma cells. Sala E, Mologni L, Truffa S, Gaetano C, Bollag GE, Gambacorti-Passerini C MOL CANCER RES 2008 6 5 751-759
17. Antitumor activity of PLX4032, a selective V600EB-Raf inhibitor, as monotherapy and in combination with capecitabine ± bevacizumab in a colorectal cancer xenograft model. Kolinsky K, Bollag G, Lee R, Packman K, Heimbrook D, Su F, Higgins B EJC SUPPL 2008 6 12 Abs 591
18. Discovery and optimization of a selective inhibitor of oncogenic B-Raf. Spevak W, Cho H, Shi S, Lam B, Guan Y, Powell B, Shi S, Zhang C, Zhang K, Tsai J, Bollag G et al AM CHEM SOC NATL MEET EXPOSITION 2009 237 March 22 Medi-086
19. Phase I study of PLX4032: Proof of concept for V600E BRAF mutation as a therapeutic target in human cancer. Flaherty K, Puzanov I, Sosman J, Kim K, Ribas A, McArthur G, Lee RJ, Grippo JF, Nolop K, Chapman P J CLIN ONCOL 2009 27 15 Suppl Abs 9000
20. PLX4032, a highly selective V600EBRAF kinase inhibitor: Clinical correlation of activity with pharmacokinetic and pharmacodynamic parameters in a phase I trial. Puzanov I, Nathanson KL, Chapman PB, Xu X, Sosman JA, McArthur GA, Ribas A, Kim KB, Grippo JF, Flaherty KT J CLIN ONCOL 2009 27 15 Suppl Abs 9021
21. Pyridoimidazolones as novel potent inhibitors of v-Raf murine sarcoma viral oncogene homologue B1 (BRAF). Niculescu-Duvaz D, Gaulon C, Dijkstra HP, Niculescu-Duvaz I, Zambon A, Menard D, Suijkerbuijk BMJM, Nourry A, Davies L, Manne H, Friedlos F et al J MED CHEM 2009 52 8 2255-2264
22. Results of a phase III, randomized, placebo-controlled study of sorafenib in combination with carboplatin and paclitaxel as second-line treatment in patients with unresectable stage III or stage IV melanoma. Hauschild A, Agarwala SS, Trefzer U, Hogg D, Robert C, Hersey P, Eggermont A, Grabbe S, Gonzalez R, Gille J, Peschel C et al J CLIN ONCOL 2009 27 17 2823-2830
23. Efficacy of PLX4032, a selective V600EB-Raf inhibitor, as monotherapy or in combination with capecitabine ± bevacizumab in a colorectal cancer xenograft model. Kolinsky KD, Su F, Bollag G, Lee R, Packman K, Schostack K, Heimbrook D, Kohles J, Higgins B GASTROINTESTINAL CANCERS SYMP 2009 January 15-17 Abs 362
24. Antitumor activity of B-Raf inhibitor (PLX4032) against a panel of human melanoma cell lines. Montecillo ML, Sondergaard J, Ribas A J INVEST MED 2009 57 1 Suppl Abs 403
25. New selective B-RAF inhibitor leads to re-differentiation and growth arrest through up-regulation of p21CIP/WAF in anaplastic thyroid carcinoma cell lines. Sala E, Mologni L, Gambacorti-Passerini C AM ASSOC CANCER RES ANN MEET 2007 98 Abs 5248
26. Early efficacy signal demonstrated in advanced melanoma in a phase I trial of the oncogenic BRAF-selective inhibitor PLX4032. Chapman P, Puzanov I, Sosman J, Kim K, Ribas A, McArthur G, Lee R, Grippo J, Nolop K, Flaherty K EJC SUPPL 2009 7 3 Abs 6BA
27. PLX4032, a selective B-RafV600E inhibitor demonstrates potent antitumor activity in preclinical melanoma models. Su F, Yang H, Higgins B, Kolinsky K, Lee R, Packman K, Schostack K, Heimbrook D, Bollag G AM ASSOC CANCER RES ANN MEET 2009 100 Abs 4420
28. Plexxikon announces encouraging data from phase 1 extension study of PLX4032 showing objective responses in metastatic melanoma patients. Plexxikon Inc PRESS RELEASE 2009 September 23
29. Plexxikon announces first patient dosed in first of two pivotal trials of PLX4032 for metastatic melanoma. Plexxikon Inc PRESS RELEASE 2009 September 29
30. Learnings from an oncogene-selective B-Raf inhibitor. Bollag G AACR-NCI-EORTC INT CONGRESS 2009 21 November 16
31. MEK1 mutations confer resistance to MEK and B-RAF inhibition. Emery CM, Vijayendran KG, Zipser MC, Sawyer AM, Niu LL, Kim JJ, Hatton C, Chopra R, Oberholzer PA, Karpova MB, MacConaill LE et al PROC NATL ACAD SCI USA 2009 106 48 20411-20416
32. Plexxikon announces first patient dosed in phase 3 trial of PLX4032 (RG7204) for metastatic melanoma. Plexxikon Inc PRESS RELEASE 2010 January 08
33. Cytostatic activity of adenosine triphosphate-competitive kinase inhibitors in BRAF mutant thyroid carcinoma cells. Salerno P, De Falco V, Tamburrino A, Nappi TC, Vecchio G, Schweppe RE, Bollag G, Santoro M, Salvatore G J CLIN ENDOCRINOL METAB 2010 95 1 450-455
34. Melanoma biology and new targeted therapy. Gray-Schopfer V, Wellbrock C, Marais R NATURE 2007 445 7130 851-857
35. Understanding melanoma signaling networks as the basis for molecular targeted therapy. Smalley KSM J INVEST DERMATOL 2010 130 1 28-37
36. A new American Joint Committee on Cancer staging system for cutaneous melanoma. Balch CM, Buzaid AC, Atkins MB, Cascinelli N, Coit DG, Fleming ID, Houghton A, Kirkwood JM, Mihm MF, Morton DL, Reintgen D et al CANCER 2000 88 6 1484-1491
37. Dacarbazine-based chemotherapy for metastatic melanoma: Thirty-year experience overview. Serrone L, Zeuli M, Sega FM, Cognetti F J EXP CLIN CANCER RES 2000 19 1 21-34
38. Mutations of the BRAF gene in human cancer. Davies H, Bignell GR, Cox C, Stephens P, Edkins S, Clegg S, Teague J, Woffendin H, Garnett MJ, Bottomley W, Davis N et al NATURE 2002 417 6892 949-954
39. V599EB-RAF is an oncogene in melanocytes. Wellbrock C, Ogilvie L, Hedley D, Karasarides M, Martin J, Niculescu-Duvaz D, Springer CJ, Marais R CANCER RES 2004 64 7 2338-2342
40. Selective Raf inhibition in cancer therapy. Khazak V, Astsaturov I, Serebriiskii IG, Golemis EA EXPERT OPIN THER TARGETS 2007 11 12 1587-1609
41. BrafV600E cooperates with Pten loss to induce metastatic melanoma. Dankort D, Curley DP, Cartlidge RA, Nelson B, Karnezis AN, Damsky WE, You MJ, DePinho RA, McMahon M, Bosenberg M NAT GENET 2009 41 5 544-552
42. New insight into BRAF mutations in cancer. Dhomen N, Marais R CURR OPIN GENET DEV 2007 17 1 31-39
43. Discovery and development of sorafenib: A multikinase inhibitor for treating cancer. Wilhelm S, Carter C, Lynch M, Lowinger T, Dumas J, Smith RA, Schwartz B, Simantov R, Kelley S NAT REV DRUG DISCOV 2006 5 10 835-844
44. Mutant V599EB-Raf regulates growth and vascular development of malignant melanoma tumors. Sharma A, Trivedi NR, Zimmerman MA, Tuveson DA, Smith CD, Robertson GP CANCER RES 2005 65 6 2412-2421
45. BRAF mutation predicts sensitivity to MEK inhibition. Solit DB, Garraway LA, Pratilas CA, Sawai A, Getz G, Basso A, Ye Q, Lobo JM, She Y, Osman I, Golub TR et al NATURE 2006 439 7074 358-362
46. The mitogen-activated protein/extracellular signal-regulated kinase kinase inhibitor AZD6244 (ARRY-142886) induces growth arrest in melanoma cells and tumor regression when combined with docetaxel. Haass NK, Sproesser K, Nguyen TK, Contractor R, Medina CA, Nathanson KL, Herlyn M, Smalley KSM CLIN CANCER RES 2008 14 1 230-239
47. Oncogenic BRAFV600E inhibits BIM expression to promote melanoma cell survival. Cartlidge RA, Thomas GR, Cagnol S, Jong KA, Molton SA, Finch AJ, McMahon M PIGMENT CELL MELANOMA RES 2008 21 5 534-544
48. Identification of direct transcriptional targets of V600EBRAF/MEK signalling in melanoma. Packer LM, East P, Reis-Filho JS, Marais R PIGMENT CELL MELANOMA RES 2009 22 6 785-798
49. Increased cyclin D1 expression can mediate BRAF inhibitor resistance in BRAF V600E-mutated melanomas. Smalley KSM, Lioni M, Palma MD, Xiao M, Desai B, Egyhazi S, Hansson J, Wu H, King AJ, Van Belle P, Elder DE et al MOL CANCER THER 2008 7 9 2876-2883
50. Genetic interaction between NRAS and BRAF mutations and PTEN/MMAC1 inactivation in melanoma. Tsao H, Goel V, Wu H, Yang G, Haluska FG J INVEST DERMATOL 2004 122 2 337-341
51. Modeling genomic diversity and tumor dependency in malignant melanoma. Lin WM, Baker AC, Beroukhim R, Winckler W, Feng W, Marmion JM, Laine E, Greulich H, Tseng H, Gates C, Hodi FS et al CANCER RES 2008 68 3 664-673
52. A role for K-ras in conferring resistance to the MEK inhibitor, CI-1040. Wang YL, Van Becelaere K, Jiang P, Przybranowski S, Omer C, Sebolt-Leopold J NEOPLASIA 2005 7 4 336-347
53. Growth factors rescue cutaneous melanoma cells from apoptosis induced by knockdown of mutated (V600E) B-RAF. Christensen C, Guldberg P ONCOGENE 2005 24 41 6292-6302
54. Elevated CRAF as a potential mechanism of acquired resistance to BRAF inhibition in melanoma. Montagut C, Sharma SV, Shioda T, McDermott U, Ulman M, Ulkus LE, Dias-Santagata D, Stubbs H, Lee DY, Singh A, Drew L et al CANCER RES 2008 68 12 4853-4861
55. A kinase switch underlies acquired resistance to BRAF inhibitors. Villanueva J, Cipolla AK, Kong J, Neri MK, Nathason KL, Lee JT, Herlyn M PIGMENT CELL MELANOMA RES 2009 22 SUPPL. 136
56. Multiple signaling pathways must be targeted to overcome drug resistance in cell lines derived from melanoma metastases. Smalley KSM, Haass NK, Brafford PA, Lioni M, Flaherty KT, Herlyn M MOL CANCER THER 2006 5 5 1136-1144
57. Topical treatment with inhibitors of the phosphatidylinositol 3'-kinase/Akt and Raf/mitogen-activated protein kinase kinase/extracellular signal-regulated kinase pathways reduces melanoma development in severe combined immunodeficient mice. Bedogni B, O'Neill MS, Welford SM, Bouley DM, Giaccia AJ, Denko NC, Powell MB CANCER RES 2004 64 7 2552-2560
58. Targeting V600EB-Raf and Akt3 using nanoliposomal-small interfering RNA inhibits cutaneous melanocytic lesion development. Tran MA, Gowda R, Sharma A, Park EJ, Adair J, Kester M, Smith NB, Robertson GP CANCER RES 2008 68 18 7638-7649
59. Transient potent BCR-ABL inhibition is sufficient to commit chronic myeloid leukemia cells irreversibly to apoptosis. Shah NP, Kasap C, Weier C, Balbas M, Nicoll JM, Bleickardt E, Nicaise C, Sawyers CL CANCER CELL (ONLINE) 2008 14 6 485-493
60. PLX4032, a selective BRAFV600E kinase inhibitor, activates the Erk pathway and enhances cell migration and proliferation of BRAFWT melanoma cells. Halaban R, Zhang WG, Bacchiocchi A, Cheng E, Parisi F, Ariyan S, Krauthammer M, McCusker JP, Kluger Y, Sznol M PIGMENT CELL MELANOMA RES 2010 23 2 190-200
61. Ovarian tumorigenesis: A proposed model based on morphological and molecular genetic analysis. Shih IM, Kurman RJ AM J PATHOL 2004 164 5 1511-1518
62. BRAF mutations characterize colon but not gastric cancer with mismatch repair deficiency. Oliveira C, Pinto M, Duval A, Brennetot C, Domingo E, Espin E, Armengol M, Yamamoto H, Hamelin R, Seruca R, Schwartz S ONCOGENE 2003 22 57 9192-9196
63. BRAF mutation in papillary thyroid carcinoma. Cohen Y, Xing M, Mambo E, Guo Z, Wu G, Trink B, Beller U, Westra WH, Ladenson PW, Sidransky D J NATL CANCER INST 2003 95 8 625-627
64. RAF inhibitors transactivate RAF dimers and ERK signalling in cells with wild-type BRAF. Poulikakos PI, Zhang C, Bollag G, Shokat KM, Rosen N NATURE 2010 464 7287 427-430
65. RAF inhibitors prime wild-type RAF to activate the MAPK pathway and enhance growth. Hatzivassiliou G, Song K, Yen I, Brandhuber BJ, Anderson DJ, Alvarado R, Ludlam MJC, Stokoe D, Gloor SL, Vigers G, Morales T et al NATURE 2010 464 7287 431-435
66. Drug discovery: Inhibitors that activate. Cichowski K, Janne PA NATURE 2010 464 7287 358-359
67. BRAF inhibitors: Research accelerates in wake of positive findings. Brower V J NATL CANCER INST 2010 102 4 214-215
68. Cell signaling by receptor tyrosine kinases: From basic principles to cancer therapy. Schlessinger J AM ASSOC CANCER RES ANN MEET 2010 101 April 19
69. Prognostic factors in metastatic melanoma: A pooled analysis of Eastern Cooperative Oncology Group trials. Manola J, Atkins M, Ibrahim J, Kirkwood J J CLIN ONCOL 2000 18 22 3782-3793
70. Revised American Joint Committee on Cancer staging criteria accurately predict sentinel lymph node positivity in clinically node-negative melanoma patients. Rousseau DL, Ross MI, Johnson MM, Prieto VG, Lee JE, Mansfield PF, Gershenwald JE ANN SURG ONCOL 2003 10 5 569-574